ICYMI, this week we had stories about the Society for Pediatric Dermatology 2022 Meeting, FDA updates, mental health, and more.
From pediatric dermatology quizzes to the latest news in telederm to practical pearls on atopic dermatitis, alopecia, and vitiligo, there’s a lot going on at the SPD 2022 47th Annual Meeting, this year in Indianapolis, Indiana.
An extraordinary display of posters at this year's Society for Pediatric Dermatology Meeting in Indianapolis, Indiana.
This week's edition of the Mainstream Patient features stories about abortions, spray sunscreen, tinted moisturizers, and more.
Click here to answer this week's poll.
It is important for pediatric and family nurse practitioners caring for patients with dermatological conditions to be comfortable talking about the conditions with children, adolescents, and their parents.
Verrica is complying with the FDA through 3 Complete Response Letters to achieve the first FDA-approved treatment of molluscum contagiosum.
The effect of acne is more than skin deep.
Cynthia J. Trickett, PA-C, MPAS, discusses the personal and clinical effects of atopic dermatitis in adult and pediatric patients at the Maui Derm NP+PA 2022 Summer Conference in Colorado Springs, Colorado.
Recent advances in technology have begun to allow the realization of personalized medicine in the practice of dermatology.
Bernard A. Cohen, MD, shares what he thinks will be most exciting at this year's Society for Pediatric Dermatology Meeting in Indianapolis, Indiana.
At the SPD 2022 47th Annual Meeting in Indianapolis, Indiana, a poster session on atopic dermatitis severity and outcomes in young children from 5 regions around the world.
Sleep disturbance is a significant factor in reduced quality of life for children and adolescents. A study at the SPD 2022 47th Annual Meeting on treating this population with dupilumab (Dupixent) to help with sleep quality showed positive results.
At the SPD 2022 47th Annual Meeting in Indianapolis, Candrice R. Heath, MD, FAAP, FAAD share compelling best practices for treating patients of color with this condition.